(Reuters) - Illumina Inc said on Monday it was cutting 5% of its global workforce to realign its operating expenses as stubborn inflation and a strong dollar weigh on the genetic sequencing equipment maker's business.
(Reuters) – Illumina Inc said on Monday it was cutting 5% of its global workforce to realign its operating expenses as stubborn inflation and a strong dollar weigh on the genetic sequencing equipment maker’s business.
The company said it was expecting to take a restructuring charge, which would include expenses related to optimizing its facilities, in the fourth quarter.
The layoffs come on the back of a near $4 billion impairment it took in the third quarter related to its cancer test unit GRAIL.
The company, which is in the process of launching its next-generation NovaSeq X DNA sequencing systems, has over 9,100 employees globally, according to its website.
(Reporting by Leroy Leo in Bengaluru; Editing by Anil D’Silva)
Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV. Learn more about Thomson Reuters products: